|Bid||140.09 x 200|
|Ask||140.13 x 100|
|Day's range||140.00 - 140.92|
|52-week range||110.76 - 144.35|
|PE ratio (TTM)||24.39|
|Earnings date||23 Jan 2018|
|Forward dividend & yield||3.36 (2.40%)|
|1y target est||146.00|
Johnson & Johnson and Bayer were recently ordered by a Philadelphia court to pay $28 million in damages to an Indiana couple, related to internal bleeding about which the companies did not sufficiently warn patients.
Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.
The stakes are high as Johnson & Johnson seeks an appeals-court ruling tossing out a $151 million judgment over its Pinnacle artificial hips in a case that could foreshadow the outcome for thousands of ...
The Health Care Select Sector SPDR ETF (XLV), which tracks the performance of the healthcare sector, rose 2.9% in November 2017.
AbbVie (ABBV) J&J's combination study evaluating Imbruvica in Waldenstrom's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, meets primary endpoint.
GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. and AstraZeneca Plc are among more than two dozen global pharmaceutical companies pledging to invest funds in the U.K. as part of a multi-billion-pound ...
The jury slapped the companies, which jointly developed the blockbuster drug, with $1.8 million in compensatory and $26 million in punitive damages, according to the couple's lawyer. The verdict marks the first trial loss in litigation over Xarelto. Bayer and J&J have won three previous cases in federal court.
The jury slapped the companies, which jointly developed the blood thinner, with $1.8 million in compensatory and $26 million in punitive damages, according to the couple's lawyer. The verdict marks the first trial loss in litigation over Xarelto. Bayer and J&J have won three previous cases in federal court.
Johnson & Johnson’s immunology portfolio, which primarily consists of Remicade, Simponi and Stelara, accounts for around 15% of the company’s value, according to our estimates.
Johnson & Johnson and Bayer AG are responsible for a woman’s injuries tied to the blood-thinning drug Xarelto and must pay more than $29 million in damages, jurors concluded in the companies’ first loss ...
AbbVie (ABBV) announces data from a phase III study on risankizumab, which shows that a significant portion of plaque psoriasis patients treated with risankizumab achieved high levels of skin clearance.
Sanofi's (SNY) head-to-head study comparing Toujeo long-acting insulin to Novo Nordisk's Tresiba long-acting insulin (insulin degludec) meets its objective.
Motley Fool investors offer up McDonald's, Brookfield Infrastructure Partners, and Altria as better income options today.
The market might be dead wrong about clinical-stage cancer company Geron, which gives risk-tolerant investors the potential for explosive gains.
Lilly (LLY) announced the label expansion of its psoriasis drug, Taltz, for the active psoriatic arthritis indication in the United States.
In 3Q17, Merck's Remicade revenues fell ~31% to $214 million compared to $311 million in 3Q16. The fall was driven by lower sales due to generic competition and biosimilars.